Testing Dermatitis Medication in Healthy Subjects
common.study.values.description
“A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis”
The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis. The study has three parts. Each participant will enroll in one part. The study will last 12 to 24 weeks, depending on part.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - LY3454738
Administered IV
Drug - LY3454738
Administered SC
Drug - Placebo
Administered IV
participant.views.study.view.additional
participant.views.study.view.scientific-title
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
common.study.values.clinical-trial-id
NCT03750643
participant.views.study.view.id
bqxAra
